ArticlePharmaceutical biology2023
Paeoniflorin suppresses the apoptosis and inflammation of human coronary artery endothelial cells induced by oxidized low-density lipoprotein by regulating the Wnt/β-catenin pathway.
Article in Pharmaceutical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Paeoniflorin Alleviates Coronary Artery Lesions in Kawasaki Disease by Activating NRF2 Pathway and Inhibiting CYP2E1 Expression.Cardiovascular drugs and therapy · 2026Article
- Paeoniflorin: a natural candidate for the treatment of metabolic diseases.Nutrition & metabolism · 2026Review
- The correlation between characteristics and pharmacological effects of monoterpene glycosides and tannins in Radix Paeoniae Alba.Journal of pharmaceutical analysis · 2026Review
- Retinal Ischemia: Therapeutic Effects and Mechanisms of Paeoniflorin.International journal of molecular sciences · 2025Article
- Paeoniflorin improves atherosclerosis by regulating the gut microbiota and fecal metabolites.mSystems · 2025Article
- Curdione protects vascular endothelial cells and atherosclerosis via the regulation of DNMT1-mediated ERBB4 promoter methylation.Open medicine (Warsaw, Poland) · 2025Article
- TRAF2 regulates the progression of pulmonary fibrosis through β-catenin-Snail signaling pathway.Frontiers in public health · 2025Article
- Therapeutic potential and pharmacological insights of total glucosides of paeony in dermatologic diseases: a comprehensive review.Frontiers in pharmacology · 2024Review
- BATF alleviates ox-LDL-induced HCAEC injury by regulating SIRT1 expression in coronary heart disease.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextPaeoniflorin (PF) contributes to improving coronary artery disease (CAD).
objectiveThis study clarified the efficiency of PF in CAD and the molecular mechanism. MATERIALS AND
methodsHuman coronary artery endothelial cells (HCAECs) were treated with oxidized low-density lipoprotein (ox-LDL; 20, 40, 80 and 160 μg/mL) and PF (0.05, 0.1 0.2 and 0.4 mM). To study cell phenotypes, HCAECs were treated with 80 μg/mL ox-LDL with or without 0.1 mM PF for 24 h, and cell viability and apoptosis were evaluated using the methyl thiazolyl tetrazolium (MTT) assay and flow cytometry, respectively. In addition, inflammatory cytokines levels were measured by enzyme-linked immunosorbent assay (ELISA). Western blot evaluated the Wnt/β-catenin pathway-related factors.
resultsox-LDL and PF (0.2 and 0.4 mM) suppressed cell viability in a dose-dependent manner. The IC DISCUSSION AND
conclusionsThis study first revealed that PF inhibited ox-LDL-induced HCAECs apoptosis and inflammation
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.